Hospira sales up by 1.4% in third quarter
LAKE FOREST, Ill. — Hospira had sales of $1 billion in third quarter 2013, the generic drug maker said.
Hospira, which specializes in making generic injectable drugs, as well as biosimilars for the European market, said the sales figures for the quarter were a 1.4% increase over the $994 million in sales reported in third quarter 2012. Profits for the quarter were $84.5 billion, compared with $78.4 billion during the same period last year.
"The third quarter was one of continued progress in several areas," Hospira CEO F. Michael Ball said. "We were especially pleased to receive European approval in the quarter for our biosimilar infliximab, Inflectra, the first monoclonal antibody to be approved in Europe."
Aprecia appoints Don Wetherhold as CEO
MASON, Ohio — Aprecia Pharmaceuticals Co. has appointed Don Wetherhold as its CEO, the company said Monday.
Wetherhold is returning to Aprecia after a term as SVP long-term care at Omnicare; prior to that, he was Aprecia’s corporate commercialization officer.
"We are thrilled to have Don back at Aprecia, and we look forward to the leadership he will bring to this role," Aprecia chairman E. Thomas Arington. "Don was instrumental in devising our commercialization strategy at Aprecia."
Aprecia’s main product is ZipDose, a fast-melting drug-delivery technology.
"I’m excited to be back at Aprecia for a number of reasons, not the least of which is the rare opportunity to be the first at something and redefine a market, which is what our breakthrough 3DP product development and manufacturing system has the potential to do," Wheterhold said.
Mylan launches generic Aciphex
PITTSBURGH — Mylan has launched its generic version of a drug used to treat gastroesophageal reflux disease, the U.S.-based generic drug maker said Monday.
Mylan announced the launch of rabeprazole sodium extended-release tablets in the 20-mg strength, a generic version of Eisai’s Aciphex. The Food and Drug Administration approved generic versions of Aciphex made by six companies on Friday.
Aciphex had sales of about $830.1 million during the 12-month period that ended in September, according to IMS Health.